Zacks Research upgraded shares of ProAssurance (NYSE:PRA – Free Report) from a hold rating to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports. Zacks Research also issued estimates for ProAssurance’s FY2025 earnings at $1.18 EPS, Q2 2026 earnings at $0.28 EPS, FY2026 earnings at $1.07 EPS and FY2027 earnings at $1.26 EPS.
ProAssurance Price Performance
Shares of PRA stock opened at $23.86 on Monday. ProAssurance has a 1-year low of $13.00 and a 1-year high of $24.14. The stock’s 50-day moving average is $23.83 and its 200 day moving average is $22.97. The company has a market cap of $1.23 billion, a P/E ratio of 25.38 and a beta of 0.12. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.26 and a quick ratio of 0.26.
ProAssurance (NYSE:PRA – Get Free Report) last posted its earnings results on Tuesday, August 5th. The insurance provider reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.33. ProAssurance had a net margin of 4.33% and a return on equity of 5.62%. The company had revenue of $271.94 million during the quarter, compared to analysts’ expectations of $266.72 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. ProAssurance’s revenue for the quarter was down 19.9% compared to the same quarter last year. Research analysts predict that ProAssurance will post 0.8 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About ProAssurance
ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.
Further Reading
- Five stocks we like better than ProAssurance
- Insider Trading – What You Need to Know
- Cybersecurity Market Set to Double: This ETF Offers Exposure
- Differences Between Momentum Investing and Long Term Investing
- Downgraded But Not Done: 3 Stocks Ready for a Market Comeback
- The Risks of Owning Bonds
- Solana Beat BTC and ETH in Q3: These 3 Stocks Saw It Coming
Receive News & Ratings for ProAssurance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProAssurance and related companies with MarketBeat.com's FREE daily email newsletter.